norcantharidin has been researched along with Kidney Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y; Luo, H; Shan, Y; Tang, C; Tian, J; Wei, J; Wen, L; Xiao, Z; Xu, Q; Zeng, D | 1 |
| Chen, Q; Ge, Y; Li, J; Li, Y; Liu, FY; Peng, YM; Sun, L; Sun, Y; Ye, K | 1 |
| Duc, HT; Dutertre-Catella, H; Liu, XH; Massicot, F; Pham-Huy, C; Warnet, JM | 1 |
1 review(s) available for norcantharidin and Kidney Diseases
| Article | Year |
|---|---|
Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Fibrosis; Humans; Kidney Diseases; Kidney Tubules; NF-kappa B; Phosphoprotein Phosphatases; Signal Transduction | 2012 |
2 other study(ies) available for norcantharidin and Kidney Diseases
| Article | Year |
|---|---|
Norcantharidin protects against renal interstitial fibrosis by suppressing TWEAK-mediated Smad3 phosphorylation.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Collagen Type I; Cytokine TWEAK; Fibronectins; Fibrosis; Kidney; Kidney Diseases; Male; Mice, Inbred C57BL; Phosphorylation; Protective Agents; Smad3 Protein; Transforming Growth Factor beta1; Ureteral Obstruction | 2020 |
In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin.
Topics: Adenosine Triphosphate; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Cell Line; Cell Separation; Cell Survival; Enzyme Inhibitors; Epoprostenol; Glutathione; Inflammation; Irritants; Kidney Diseases; Lipopolysaccharides; LLC-PK1 Cells; Macrophage Activation; Macrophages; Mice; Nitric Oxide; Phosphoprotein Phosphatases; Prostaglandins; Swine; Thromboxane B2 | 2005 |